With the advances in biomaterial sciences, the last decade has seen the development of a variety of foldable intraocular lens (IOL) materials. Hydrogel, soft acrylic and silicone IOLs allow smaller incisions to be used than with polymethylmethacrylate lenses, l but their long term safety has not been established.
Hydrogel lenses are generally manufactured from poly-hydroxy-ethyl-methacrylate (Poly-HEMA). 2 Various studies 3 suggest that hydrogel lenses are very biocompatible and resistant to YAG laser damage and have better biological tolerance. We have recently encountered seven cases of IOL opalescence (Fig. 1) appearing at or after 6 months post-operatively. All these patients had uncomplicated phacoemulsification with an uneventful post-operative period until this opalescence appeared. All patients with IOL opalescence had only one common factor: the IOL implanted was a hydrogel IOL. One of these seven patients showed a drop in visual acuity and this case is reported here.
Case report
Phacoemulsification was performed on the right eye of an 87-year-old woman. A 3.5 mm temporal clear corneal section was used. The surgery was performed using sodium hyaluronate as viscoelastic and an Alcon phacoemulsifier. The lens was inspected and noted to be clear before implantation. No irrigating solutions were used to rinse the lens before implantation. The immediate post-operative period was uneventful. The best corrected visual acuity in the operated eye at the 2 week post-operative visit was 6/12. When the patient was reviewed in clinic after 6 months, lens opalescence ( Fig. 1 ) was noticed for the first time. On slit-lamp examination the optical section revealed that the opalescence involved both the anterior and posterior surfaces of the IOL (Fig. 2) . On retroillumination the red glow had a whitish tinge with loss of sharpness (Fig. 3) . The patient had a best-corrected visual acuity of 6/36. There was early posterior capsular opacification. The fundus examination did not reveal any abnormality to explain the loss in visual acuity. A YAG capsulotomy was done with no improvement in visual acuity. The cause of decrease in visual acuity in this case has been opalescence of the IOL. The option of explanation and IOL exchange has been considered and is being discussed with the patient.
Comment
This is amongst the first reports of opalescence of hydrogel IOLs in literature. Previously opalescence has been reported with silicone IOLs. Mazzocc0 2 has reported the slight opalescence with original STAAR silicon polymer (RMX-1). He stated that this does not harm the eye. However, this opalescence had made YAG capsulotomy more difficult for some investigators. Many of the polymers used nowadays are made by minor alteration of the side-chain component of the acrylate/methacrylate polymer backbone, resulting in materials with differing physical and biological properties. The 10L used in the present case was a hydrogel 10L, which is composed of ultrapure Poly HEMA, methylmethacrylate (MMA) and an ultraviolet absorber.4 At present we are unable to relate the opalescence to any clinical event. It seems that the physical properties of the polymer are responsible for it. A large number of patients in our series have this opalescence and might ultimately present with a decrease in visual acuity and require explanation. We have taken up an audit of all patients in whom this particular type of hydrogel 10L has been implanted. The present case may be an isolated example of an adverse event in hydrogel's material history (which is very short) but long-term follow-up clinical studies are lacking. This case emphasises the need for careful long-term follow-up of all the patients receiving this particular 10L material.
Visual impairment is common among elderly people and is associated with falls, hip fracture and reductions in functional ability and quality of life.1 A recent survey in London found 30% of people aged 65 years and over to have a visual acuity of less than 6/12, which in 72% of cases could potentially be improved?
Since 1990, general practitioners have been required to offer annual screening to all patients aged 75 years or over, including an assessment of vision. A recent report for the Department of Health recommended that further research was needed to clarify the use of 'over-75 checks' as an outcome measure for the quality of cataract services. 3 The aim of this study was to determine current practice with regard to systematic screening for visual impairment as part of the over-75 checks.
